Biblio
“Diagnostic Performance of Cerebrospinal Fluid Neurofilament Light Chain and Soluble Amyloid-β Protein Precursor β in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1515-1528, 2023.
, “Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, “Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 82, no. 2, pp. 781-790, 2021.
, “APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.”, J Alzheimers Dis, vol. 69, no. 3, pp. 783-793, 2019.
, “Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort.”, J Alzheimers Dis, vol. 63, no. 1, pp. 373-381, 2018.
, “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
, “A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).”, J Alzheimers Dis, vol. 63, no. 4, pp. 1509-1522, 2018.
, “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
, “Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 59, no. 3, pp. 1017-1026, 2017.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.”, J Alzheimers Dis, vol. 54, no. 1, pp. 383-95, 2016.
,